Creating targeted treatments for Multiple Myeloma using SETD8 inhibitors
Official title: Developing Lysine Methyltransferase SETD8 Selective Inhibitors for Treating Multiple Myeloma
Funded at Icahn School of Medicine at Mount Sinai · NIH-11221119 · Data updated 2026-11-12
This study is looking at new ways to help people with Multiple Myeloma by testing special compounds that can block a protein called SETD8, which helps cancer cells grow, with the hope of making those cells die off more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 11, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $701,330 |
| NIH project number | 1R01CA290791-01A1 |
| Project ID | NIH-11221119 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Multiple Myeloma, particularly those with high levels of SETD8 expression.
✕Less likely to help
Patients with other types of cancers or those whose Multiple Myeloma does not involve SETD8 overexpression may not benefit from this research.
What this research studies
This research focuses on developing selective inhibitors for SETD8, a protein that plays a crucial role in the growth of Multiple Myeloma (MM) cells. By inhibiting SETD8, the researchers aim to disrupt the cancer cell cycle and promote cell death specifically in MM cells that overexpress this protein. The approach involves testing new compounds that have shown promise in preliminary studies to effectively target and inhibit SETD8, potentially leading to improved treatment options for patients with MM.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for patients suffering from Multiple Myeloma.
How similar studies have gone: Other research has shown promising results with similar approaches targeting SETD8 in cancer treatment, indicating potential for success in this area.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Jin, Jian — Icahn School of Medicine at Mount Sinai
- Study coordinator: Jin, Jian
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.